FFA
AMRX icon

Frazier Financial Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Frazier Financial Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-490
Closed -$4.08K – 657
2024
Q3 		$4.08K Sell
490
-1,154
-70% -$9.02K ﹤0.01% 569
2024
Q2 		$10.4K Buy
1,644
+1,045
+174% +$6.63K 0.01% 426
2024
Q1 		$3.63K Buy
599
+354
+144% +$2K ﹤0.01% 660
2023
Q4 		$1.49K Buy
+245
New +$1.09K ﹤0.01% 711

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Frazier Financial Advisors's AMRX Position: Q4 2024 in Review

Frazier Financial Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q4 2024, closing a stake of 490 shares — an estimated $4.08K sold.

Frazier Financial Advisors first reported a position in AMRX in Q4 2023 and held it in 4 quarters. The position peaked at $10.4K in Q2 2024. 199 funds tracked by Wall St. Rank hold AMRX as of Q4 2024.

  • Frazier Financial Advisors reported no remaining Amneal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Frazier Financial Advisors sold 490 Amneal Pharmaceuticals shares in Q4 2024, an estimated $4.08K.
  • Frazier Financial Advisors first reported a position in Amneal Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Frazier Financial Advisors's Amneal Pharmaceuticals position peaked at $10.4K in Q2 2024.
  • 199 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2024.

Based on Frazier Financial Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.